Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. IDXX
IDXX logo

IDXX Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
601.650
Open
600.135
VWAP
596.12
Vol
263.43K
Mkt Cap
47.68B
Low
585.720
Amount
157.04M
EV/EBITDA(TTM)
32.12
Total Shares
79.62M
EV
48.35B
EV/OCF(TTM)
40.91
P/S(TTM)
11.27
IDEXX Laboratories, Inc. develops, manufactures and distributes products and provides services primarily for the companion animal veterinary, livestock and poultry, dairy and water testing industries. The Company also provides human medical point-of-care and laboratory diagnostics. Its segments include Companion Animal Group (CAG), Water quality products (Water), and Livestock, Poultry and Dairy (LPD). The CAG segment offers diagnostic and information management-based products and services for the companion animal veterinary industry, including in-clinic diagnostic solutions, outside reference laboratory services, and veterinary software and services. The Water segment provides testing solutions for accurate detection and quantification of various microbiological parameters in water. The LPD segment provides diagnostic tests, services, and related instrumentation that are used to manage the health status of livestock and poultry, and to improve the quality and safety of milk.
Show More

Events Timeline

(ET)
2026-02-02
06:40:00
Company Sees FY26 Revenue Guidance of $4.632B to $4.72B
select
2026-02-02
06:40:00
IDEXX Reports Q4 Revenue of $1.09B
select
2026-01-13 (ET)
2026-01-13
09:00:00
IDEXX Laboratories Appoints Michael Erickson as New CEO
select

News

Fool
2.0
02-25Fool
BAMCO Reduces Stake in Vail Resorts
  • Share Reduction Details: According to a SEC filing dated February 17, 2026, BAMCO Inc sold 892,764 shares of Vail Resorts during Q4, reducing its holdings to 4,809,928 shares, with a quarter-end valuation decline of $214.19 million reflecting both trading activities and price movements.
  • Asset Management Ratio Shift: Following this sale, Vail Resorts now represents only 1.73% of BAMCO's 13F reportable AUM, indicating investor concerns regarding the resilience of high-end vacation spending in an uncertain travel environment.
  • Company Financial Overview: As of February 17, 2026, Vail Resorts' stock price stood at $137.75, down 8.9% over the past year, underperforming the S&P 500 by 23.36 percentage points, which reflects market caution regarding its future growth prospects.
  • Profitability Model Analysis: Vail Resorts generates revenue primarily from lift ticket sales, lodging, and ancillary resort services; while the Epic Pass offers predictable cash flow, the company's high fixed costs mean that even slight declines in visitor numbers can significantly pressure earnings.
NASDAQ.COM
2.0
02-25NASDAQ.COM
BAMCO Inc Sells Shares of Vail Resorts
  • Share Sale Details: BAMCO Inc sold 892,764 shares of Vail Resorts in Q4 for approximately $131.38 million, reflecting market concerns about high-end vacation spending, which has led to a decline in the company's investment position.
  • Value Decline: The transaction resulted in a $214.19 million decrease in BAMCO's position value in Vail Resorts, with the current holding of 4,809,928 shares valued at $638.76 million, indicating pressure on the company within the luxury travel market.
  • Portfolio Impact: Vail Resorts now represents 1.73% of BAMCO's 13F reportable assets under management, no longer being among the top five holdings, which suggests a weakening investor confidence in the company.
  • Market Performance Analysis: As of February 17, 2026, Vail Resorts' stock price stood at $137.75, down 8.9% over the past year, underperforming the S&P 500 by 23.36 percentage points, reflecting a cautious market outlook on its future growth.
Barron's
5.0
02-20Barron's
Al Gore's Investment Firm Acquires Spotify Shares and Divests from Analog Devices
  • Investment Changes: Generation Investment Management, co-founded by Al Gore, exited two semiconductor companies in Q4.
  • New Acquisitions: The firm invested in shares of a trending streaming provider during the same period.
Fool
8.5
02-20Fool
Idexx Laboratories: A New Opportunity in Pet Health Investment
  • Consistent Investment Returns: Since 1994, Idexx Laboratories has achieved an annual return of 20%, transforming an initial $5,000 investment into $1.6 million, demonstrating its strong performance and long-term investment potential in the pet health sector.
  • Innovative Products Driving Revenue: The InVue DX instrument, successfully launched in 2025, saw nearly 6,400 placements within the year, expected to become one of the company's key products, particularly in the area of pet cancer detection, further driving revenue growth.
  • Stable Recurring Revenue: In the most recent quarter, 92% of sales from Idexx's consumer animal group came from recurring revenue, ensuring stable cash flow and laying a solid foundation for future growth.
  • Future Growth Potential: Idexx anticipates sales, earnings per share, and recurring revenue growth of 10%, 14%, and 8% respectively in 2025, and despite a current P/E ratio of 43, its stability and ongoing growth make it a compelling long-term investment.
Yahoo Finance
9.5
02-15Yahoo Finance
IDEXX Laboratories Reports Strong Q4 2025 Earnings Amid Target Revisions
  • Strong Performance: IDEXX Laboratories reported Q4 2025 revenue of $1.09 billion, a 14% increase year-over-year, surpassing analyst expectations of $1.072 billion, demonstrating robust performance in the medical technology sector.
  • Earnings Per Share Growth: The company’s earnings per share rose 18% to $3.08, exceeding the market estimate of $2.93, reflecting its sustained profitability and a gross margin of 61.7%.
  • Core Business Growth: The companion animal segment grew 15% to $998 million, driven by strong instrument revenue, which surged 76% year-over-year, indicating robust market demand.
  • Cautious Future Outlook: While IDEXX expects 2026 revenue between $4.63 billion and $4.72 billion, BTIG analysts noted a 200-basis-point drag from fewer pet visits among lower-income owners, although a 4% global price growth is anticipated.
NASDAQ.COM
2.0
02-13NASDAQ.COM
IDXX Options Trading Analysis and Risks
  • Options Selling Risk: Selling puts on IDXX does not provide the same upside potential as owning shares, as the seller only acquires shares if the contract is exercised, necessitating careful risk-reward assessment.
  • Yield Analysis: If IDXX's stock does not fall by 11.5%, the put seller only earns an 8.5% annualized return, with an effective cost basis of $540 per share after accounting for transaction costs.
  • Historical Volatility: IDXX's historical volatility stands at 41%, and when combined with fundamental analysis, it aids investors in determining whether selling puts at the $560 strike price is worthwhile, balancing risks against potential rewards.
  • Market Trading Dynamics: On Friday, the put volume among S&P 500 components reached 1.33 million contracts, matching call volume, indicating higher demand for puts than the long-term median, reflecting investor expectations of market volatility.
Wall Street analysts forecast IDXX stock price to rise
10 Analyst Rating
Wall Street analysts forecast IDXX stock price to rise
7 Buy
3 Hold
0 Sell
Moderate Buy
Current: 0.000
sliders
Low
750.00
Averages
792.78
High
850.00
Current: 0.000
sliders
Low
750.00
Averages
792.78
High
850.00
Piper Sandler
Neutral
downgrade
$775 -> $750
AI Analysis
2026-02-09
Reason
Piper Sandler
Price Target
$775 -> $750
AI Analysis
2026-02-09
downgrade
Neutral
Reason
Piper Sandler lowered the firm's price target on Idexx Laboratories to $750 from $775 and keeps a Neutral rating on the shares following quarterly results. The firm says its updated price target primarily reflects its updated multiple and rolling forward of estimates to 2027 from 2026.
Barclays
Glen Santangelo
Overweight
downgrade
$850 -> $800
2026-02-05
Reason
Barclays
Glen Santangelo
Price Target
$850 -> $800
2026-02-05
downgrade
Overweight
Reason
Barclays analyst Glen Santangelo lowered the firm's price target on Idexx Laboratories to $800 from $850 and keeps an Overweight rating on the shares. The firm updated the company's model post the Q4 repot, saying the fiscal 2026outlook "underwhelmed."
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for IDXX
Unlock Now

Valuation Metrics

The current forward P/E ratio for IDEXX Laboratories Inc (IDXX.O) is 47.56, compared to its 5-year average forward P/E of 49.98. For a more detailed relative valuation and DCF analysis to assess IDEXX Laboratories Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
49.98
Current PE
47.56
Overvalued PE
62.19
Undervalued PE
37.78

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
34.99
Current EV/EBITDA
33.89
Overvalued EV/EBITDA
43.32
Undervalued EV/EBITDA
26.67

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
11.20
Current PS
11.74
Overvalued PS
13.67
Undervalued PS
8.73

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

what is a good buy right now
Intellectia · 32 candidates
Analyst Consensus: Strong Buy, Moderate BuyQuarter Eps Yoy Growth: 15.0% - 100.0%Target Price Upside Potential: MoreAbovePrice, AbovePriceIs Index Component: GSPC, NDXOne Week Rise Prob: 60 - 100One Week Predict Return: 0.0% - 100.0%
Ticker
Name
Market Cap$
top bottom
TPR logo
TPR
Tapestry Inc
26.06B
BK logo
BK
Bank of New York Mellon Corp
81.14B
TTD logo
TTD
Trade Desk Inc
13.04B
GPN logo
GPN
Global Payments Inc
18.87B
MDB logo
MDB
MongoDB Inc
27.39B
MA logo
MA
Mastercard Inc
492.21B
which stock price above $100 but bearish
Intellectia · 61 candidates
Price: >= $100.00Option Sentiments: Bearish
Ticker
Name
Market Cap$
top bottom
TSM logo
TSM
Taiwan Semiconductor Manufacturing Co Ltd
1.69T
MA logo
MA
Mastercard Inc
473.76B
GE logo
GE
General Electric Co
335.96B
KLAC logo
KLAC
KLA Corp
199.72B
BLK logo
BLK
BlackRock Inc
183.61B
GEV logo
GEV
GE Vernova Inc
181.21B

Whales Holding IDXX

M
Martin Currie Ltd.
Holding
IDXX
+9.05%
3M Return
L
Liontrust Asset Management PLC
Holding
IDXX
+8.29%
3M Return
I
Inspire Investing, LLC
Holding
IDXX
+6.25%
3M Return
S
Stephens Investment Management Group, LLC
Holding
IDXX
+6.12%
3M Return
C
Comgest S.A.
Holding
IDXX
+4.94%
3M Return
T
TimesSquare Capital Management, LLC
Holding
IDXX
+4.29%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is IDEXX Laboratories Inc (IDXX) stock price today?

The current price of IDXX is 600.99 USD — it has increased 0.36

What is IDEXX Laboratories Inc (IDXX)'s business?

IDEXX Laboratories, Inc. develops, manufactures and distributes products and provides services primarily for the companion animal veterinary, livestock and poultry, dairy and water testing industries. The Company also provides human medical point-of-care and laboratory diagnostics. Its segments include Companion Animal Group (CAG), Water quality products (Water), and Livestock, Poultry and Dairy (LPD). The CAG segment offers diagnostic and information management-based products and services for the companion animal veterinary industry, including in-clinic diagnostic solutions, outside reference laboratory services, and veterinary software and services. The Water segment provides testing solutions for accurate detection and quantification of various microbiological parameters in water. The LPD segment provides diagnostic tests, services, and related instrumentation that are used to manage the health status of livestock and poultry, and to improve the quality and safety of milk.

What is the price predicton of IDXX Stock?

Wall Street analysts forecast IDXX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IDXX is792.78 USD with a low forecast of 750.00 USD and a high forecast of 850.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is IDEXX Laboratories Inc (IDXX)'s revenue for the last quarter?

IDEXX Laboratories Inc revenue for the last quarter amounts to 1.09B USD, increased 14.28

What is IDEXX Laboratories Inc (IDXX)'s earnings per share (EPS) for the last quarter?

IDEXX Laboratories Inc. EPS for the last quarter amounts to 3.08 USD, increased 17.56

How many employees does IDEXX Laboratories Inc (IDXX). have?

IDEXX Laboratories Inc (IDXX) has 11000 emplpoyees as of March 11 2026.

What is IDEXX Laboratories Inc (IDXX) market cap?

Today IDXX has the market capitalization of 47.68B USD.